Immatics NV (IMTX) advanced nearly 4.7% in pre-market trading to $9.10 after the company announced a $150 million underwritten public offering of common shares and pre-funded warrants.
The offering consists of 12,945,916 common shares priced at $8.69 each, alongside 4,315,304 pre-funded warrants at the same price. The proceeds will support the German biotech’s development pipeline, including its PRAME-targeted therapies and clinical programs.
Goldman Sachs reiterated a Buy rating on Immatics shares in early pre-market activity, aligning with the broader analyst consensus. Coverage firms collectively maintain a Strong Buy rating, with a 12-month price target range of $17 to $19. The upgrade followed the company’s second-quarter 2026 interim financial results, which showed a bottom-line earnings beat and clinical milestones remaining on track.
The stock’s 52-week high stands at $12.41, with the move occurring as the NASDAQ Composite traded higher, providing a supportive macro backdrop for growth-oriented biotech names. Immatics’ focus on its PRAME-targeted pipeline and the potential for its first commercial product continues to underpin investor interest.
